ANTABIO Awarded Up to $8.9M from CARB-X to Accelerate the Development of Its New Treatment For Chronic Infections in Cystic Fibrosis Patients
Labège, France, 25 July, 2017 – Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs…